

	<b>ACCREDITATION DOCUMENT</b>	<b>F-06/02</b> <b>Issue Date: 18/08/2020</b> <b>Rev. No: 09</b> <b>LAB 029</b>
---	-----------------------------------	---

## **Accreditation No: LAB 029**

### **Awarded to**

**Shaigan Pharmaceuticals Research and Testing Laboratories,  
14-km, Adyala Road, Rawalpindi City,  
Pakistan.**

The scope of accreditation is in accordance with the standard specifications outlined in the following page(s) of this document. The accredited scope shall be visible and legible in areas such as customer service, sample-receiving section etc and shall not mislead its users.

The accreditation was first time granted on **19-03-2009** by Pakistan National Accreditation Council.

The laboratory complies with the requirements of **ISO/IEC 17025:2017**.

The accreditation requires regular surveillance, and is valid until **30-08-2027**.

The decision of accreditation made by Pakistan National Accreditation Council implies that the organization has been found to fulfill the requirements for accreditation within the scope.

The organization however, itself is responsible for the results of performed measurements/tests.

**PAKISTAN NATIONAL ACCREDITATION COUNCIL**

**07-10-2024**  
Date

**SD**  
Director General

	<b>ACCREDITATION DOCUMENT</b>	<b>F-06/02</b> <b>Issue Date: 18/08/2020</b> <b>Rev. No: 09</b> <b>LAB 029</b>
---	-----------------------------------	---

## Testing Laboratory.

Accreditation Scope of Shaigan Pharmaceuticals Research and Testing Laboratories. Rawalpindi, Pakistan.

Permanent laboratory premises

Materials/Products tested	Testing field (e.g. environmental testing or mechanical testing)	Types of test/ Properties measured	Reference to standardized method (e.g. ISO 14577-1:2003)/ Internal method reference
<b>Bexus 250 Tablets</b>	Pharmaceutical Testing	Quantitative Analysis	USP 2020 Vol.2 ; Page 2609 -2611
		Uniformity of weight	BP 2021 Vol. V Page A413
		Disintegration test	BP 2021 Vol. V Page A389
<b>Bexus 500 Tablets</b>	Pharmaceutical Testing	Quantitative Analysis	USP 2020 Vol.2 ; Page 2609 -2611
		Uniformity of weight	BP 2021 Vol. V Page A413
		Disintegration test	BP 2021 Vol. V Page A389
<b>Bexus 750 Tablets</b>	Pharmaceutical Testing	Quantitative Analysis	USP 2020 Vol.2 ; Page 2609 -2611
		Uniformity of weight	BP 2021 Vol. V Page A413
		Disintegration test	BP 2021 Vol. V Page A389
<b>Bexus 250 Infusion</b>	Pharmaceutical Testing	Quantitative Analysis	JP XVII Page 1156
		pH	In-house (3/QC/PTP/001)
<b>Bexus 500 Infusion</b>	Pharmaceutical Testing	Quantitative Analysis	JP XVII Page 1156
		pH	In-house (3/QC/PTP/002)
<b>Bexus 750 Infusion</b>	Pharmaceutical Testing	Quantitative Analysis	JP XVII Page 1156
		pH	In-house (3/QC/PTP/003)
<b>Clozox T- Cream</b>	Pharmaceutical Testing	Quantitative Analysis	USP 2020 Vol. 1 Page 1119
		pH	In-house (3/QC/PTP/041)
<b>Clozox 0.1g Tablets</b>	Pharmaceutical Testing	Quantitative Analysis	In-house (3/QC/PTP/144)
		Friability	BP 2021 Vol. V Page A581
<b>Clozox 0.5g Tablets</b>	Pharmaceutical Testing	Quantitative Analysis	In-house (3/QC/PTP/063)
		Friability	BP 2021 Vol. V Page A581
<b>Clozox V- Cream</b>	Pharmaceutical Testing	Quantitative Analysis	USP 2020 Vol. 1 Page 1119
		pH	In-house (3/QC/PTP/042)
<b>Clycin V Cream</b>	Pharmaceutical Testing	Quantitative Analysis	USP 2020 Vol. 1 Page 1071
		pH	USP 2020 Vol. 1 Page 1071
<b>Clycin T Lotion</b>	Pharmaceutical Testing	Quantitative Analysis	In-house (3/QC/PTP/133)
		pH	In-house (3/QC/PTP/133)
<b>Famot 20 Tablets</b>	Pharmaceutical Testing	Quantitative Analysis	BP 2021 Vol. III Page 623-625
		Disintegration test	BP 2021 Vol. V Page A389
<b>Famot 40 Tablets</b>	Pharmaceutical Testing	Quantitative Analysis	BP 2021 Vol. III Page 623-625
		Disintegration test	BP 2021 Vol. V Page A389

**07-10-2024**

Date

Sd

Director

	<b>ACCREDITATION DOCUMENT</b>	<b>F-06/02</b> <b>Issue Date: 18/08/2020</b> <b>Rev. No: 09</b> <b>LAB 029</b>
---	-----------------------------------	---

Materials/Products tested	Testing field (e.g. environmental testing or mechanical testing)	Types of test/ Properties measured	Reference to standardized method (e.g. ISO 14577-1:2003)/ Internal method reference
Fudic Cream	Pharmaceutical Testing	Quantitative Analysis	BP 2021 Vol. III Page 693-694
		pH	BP 2021 Vol. III Page 693-694
Warfin 1mg Tablets	Pharmaceutical Testing	Quantitative Analysis	BP 2021 Vol. III Page 1460-1461
		Friability	BP 2021 Vol. V Page A581
		Disintegration test	BP 2021 Vol. V Page A389
Warfin 2.5mg Tablets	Pharmaceutical Testing	Quantitative Analysis	BP 2021 Vol. III Page 1460-1461
		Friability	BP 2021 Vol. V Page A581
		Disintegration test	BP 2021 Vol. V Page A389
Warfin 5.0mg Tablets	Pharmaceutical Testing	Quantitative Analysis	BP 2021 Vol. III Page 1460-1461
		Friability	BP 2021 Vol. V Page A581
		Disintegration test	BP 2021 Vol. V Page A389
Esso 40 capsules	Pharmaceutical Testing	Quantitative Analysis	USP 2020 Vol. 1 Page 1716-1720
Esso 20 capsules	Pharmaceutical Testing	Quantitative Analysis	USP 2020 Vol. 1 Page 1716-1720
Peflox Tablets	Pharmaceutical Testing	Quantitative Analysis	In-house (3/QC/PTP/069)
		Uniformity of weight	BP 2021 Vol. V Page A413
		Disintegration test	BP 2021 Vol. V Page A389
Zepar Tablets	Pharmaceutical Testing	Quantitative Analysis	In-house (3/QC/PTP/073)
		Uniformity of weight	BP 2021 Vol. V Page A413
		Disintegration test	BP 2021 Vol. V Page A389
Zepar Suspension	Pharmaceutical Testing	Quantitative Analysis	In-house (3/QC/PTP/059)
		pH	In-house (3/QC/PTP/059)
Ergomin tablets	Pharmaceutical Testing	Quantitative Analysis	USP 2020 Vol. 2 Page 2887-2888
Esso 40 I.V	Pharmaceutical Testing	Quantitative Analysis	In-house (3/QC/PTP/004)
		pH	In-house (3/QC/PTP/004)
Water For Injection	Pharmaceutical Testing	pH	BP 2021 Vol. II Page 1297
		Conductivity	USP 2020 Vol. 2 Page 4653
Albendazole	Pharmaceutical Testing	Quantitative analysis	USP 2020 Vol. 1 Page 102
		Identification	USP 2020 Vol. 1 Page 102
Clindamycin Phosphate	Pharmaceutical Testing	Quantitative analysis	USP 2020 Vol. 1 Page 1069-1071
		Identification	
	Pharmaceutical Testing	pH Water content	USP 2020 Vol. 1 Page 1069-1071
Clotrimazole	Pharmaceutical Testing	Quantitative analysis	USP 2020 Vol. 1 Page 1118-1119
		Identification	

**07-10-2024**

Date

Sd

Director

	<b>ACCREDITATION DOCUMENT</b>	<b>F-06/02</b> <b>Issue Date: 18/08/2020</b> <b>Rev. No: 09</b> <b>LAB 029</b>
---	-----------------------------------	---

<b>Famotidine</b>	Pharmaceutical Testing	Quantitative analysis	BP 2021 Vol. 1 Page 1015
		Identification	

Materials/Products tested	Testing field (e.g. environmental testing or mechanical testing)	Types of test/ Properties measured	Reference to standardized method (e.g. ISO 14577-1:2003)/ Internal method reference
<b>Pefloxacin Mesylate</b>	Pharmaceutical Testing	Quantitative analysis	In-house (3/QC/SAPA/032)
		Identification	BP 2021 Vol. II Page 548-549
		pH	
		Water content	
<b>Warfarin Sodium Clathrate.</b>	Pharmaceutical Testing	Quantitative analysis	BP 2021 Vol. II Page 1292-1293
		Identification	
		pH	
		Water content	
<b>Esomeprazole Sodium</b>	Pharmaceutical Testing	Assay	BP 2021 Vol. II Page 1292-1293
		Water Content	
<b>Methyl Ergometrine Maleate</b>	Pharmaceutical Testing	Assay	USP 2020 Vol. 2 Page 2885-2886
		Identification	
		pH	
<b>Levofloxacin hemi hydrate</b>	Pharmaceutical Testing	Quantitative analysis	USP 2020 Vol. 2 Page 2606-2608
		Identification	
		Water content	
<b>Fusidic Acid</b>	Pharmaceutical Testing	Quantitative analysis	BP 2021 Vol. I Page 1142
		Identification	
		Water content	

**07-10-2024**

Date

Sd

Director